Aarey Drugs & Pharmaceuticals Limited

Web: aareydrugs.com NSE: AAREYDRUGS BSE: 524412 SECTOR: Healthcare - Pharmaceuticals & Biotechnology | Add Note | View Notes

96 2(2%)

Near 52W High of 100

Volume

1L as on 23, Jun

Open

High

Low

VWAP

52 Week High

100

52 Week Low

Viand Research Rating

Quality Score

20/100

Growth Score

29/100

Valuation Score

50/100

Momentum Score

45/100

Analyst Recommendations

BUY/SELL

Hold | Buy | Strong Buy

Analyst Price Target

Market Cap (cr)

272

No. of Shares

3.09

P/E

P/B

1.22

Face Value

Div. Yield

Book Value (TTM)

CASH

DEBT

EPS (TTM)

ROE

4.53

ROCE

Profit Growth

Listing Date

06-Aug-21

Promoter Holding

37.71%

FII Holding

4.81%

DII Holding

1.62%

Price Chart

Price Performance

1 Week15%

1 Month9%

3 Months0%

6 Months0%

1 Year0%

YTD0%

Moving Average

5 Day SMA85

10 Day SMA82

20 Day SMA80

30 Day SMA82

50 Day SMA82

61 Day SMA84

80 Day SMA0

200 Day SMA0

PIVOT LEVEL

	Standard	Camarilla	Fibonacci	Woodie's
Resistance 3	94	89	91	96
Resistance 2	91	88	89	92
Resistance 1	89	88	88	91
Pivot Point	86	87	86	87
Support 1	84	87	84	87
Support 2	81	87	83	82
Support 3	80	86	81	82

Competitors/Peers

#	Symbol	MCAP	LTP	1W	1M	6M	1Y	P/E	Ind PE	Debt/Eq	NP Qtr Rs.Cr.
1	SUNPHARMA	4,56,655	1899	0%	2%	9%	21%	37	57.7	0.07	11509
2	DIVISLAB	2,43,196	9161	2%	8%	44%	51%	69	57.7	0	2568
3	TORNTPHARM	1,84,303	4846	2%	3%	12%	36%	72	57.7	1.79	2138
4	APOLLOHOSP	1,24,834	8650	1%	1%	12%	10%	58	57.7	0.9	2003
5	ZYDUSLIFE	1,12,897	1132	4%	2%	26%	13%	20	57.7	0.46	5124
6	CIPLA	1,11,346	1385	2%	5%	3%	12%	22	57.7	0.02	3862
7	LAURUSLABS	99,634	1844	3%	3%	75%	114%	0	57.7	0.48	890
8	DRREDDY	96,962	1151	2%	2%	11%	8%	20	57.7	0.2	4158
9	MAXHEALTH	96,646	985	1%	10%	8%	14%	0	57.7	0.32	1442
10	LUPIN	96,620	2113	1%	11%	8%	10%	23	57.7	0.29	5355
Load More

Shareholding Pattern (%)

	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022	Dec 2021	Sep 2021
Promoters	(0.01) 37.71%	(-1.31) 37.71%	(-5.81) 39.05%	(0.01) 44.80%	(0.01) 44.80%	(0.01) 44.80%	(-0.61) 44.80%	(0.21) 45.44%	(0.01) 45.28%	(-4.81) 45.28%	(0.01) 50.04%	(0.01) 50.04%	(0.01) 50.04%	(0.01) 50.05%	(0.01) 50.04%	(0.01) 50.04%	(2.01) 50.03%	(0.01) 48.06%	(-1.31) 48.05%	(0.01) 49.38%
FIIs	(0.61) 4.81%	(0.31) 4.18%	(2.71) 3.86%	(-0.81) 1.13%	(-0.41) 1.97%	(0.01) 2.34%	(-0.41) 2.34%	(-0.71) 2.75%	(0.01) 3.40%	(-0.41) 3.40%	(-0.11) 3.83%	(0.01) 3.94%	(0.01) 3.92%	(0.01) 3.92%	(-0.11) 3.92%	(0.11) 3.98%	(-0.31) 3.92%	(0.01) 4.23%	(-0.21) 4.26%	(0.01) 4.47%
DIIs	(0.01) 1.62%	(1.61) 1.62%	(0.01) 0.00%	(0.01) 0.00%	(0.01) 0.00%	(0.01) 0.00%	(0.01) 0.00%	(0.01) 0.00%	(0.01) 0.00%	(0.01) 0.00%	(0.01) 0.00%	(0.01) 0.00%	(0.01) 0.00%	(0.01) 0.00%	(0.01) 0.00%	(0.01) 0.00%	(0.01) 0.00%	(0.01) 0.00%	(0.01) 0.00%	(0.01) 0.00%
Public	55.87%	56.49%	57.09%	54.07%	53.23%	52.86%	52.86%	51.81%	51.32%	51.31%	46.12%	46.01%	46.03%	46.04%	46.04%	45.97%	46.04%	47.70%	47.69%	46.14%
No. of Shareholders	13,478	14,188	14,063	14,897	15,796	16,257	16,288	16,676	16,179	16,843	15,269	16,086	17,538	17,699	17,785	17,649	17,777	17,565	13,658	13,158

Quarterly Results

	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022	Dec 2021	Sep 2021
Sales	44.63	189.47	96.43	84.16	102.21	108.1	133.79	105.14	126.91	210.35	76.48	57.83	50.96	162.88	62.47	76.26	118.84	120.25	140.27	134.65
Sales Growth % (YoY)	-56%	75%	-28%	-20%	-19%	-49%	75%	82%	149%	29%	22%	-24%	-57%	35%	-55.5%	-43.4%	21.9%	-32.5%	47%	170%
Sales Growth % (QoQ)	-76.4%	96.5%	14.6%	-17.7%	-5.4%	-19.2%	27.2%	-17.2%	-39.7%	175%	32.2%	13.5%	-68.7%	160.7%	-18.1%	-35.8%	-1.2%	-14.3%	4.2%	-
Expenses	43.31	185.13	97.94	81.52	100.5	112.31	131.59	101.42	125.73	211.79	73.78	55.99	49.62	160.36	60.94	71.99	117.93	118.38	137.21	131.23
Operating Profit	1.32	4.34	-1.51	2.64	1.71	-4.21	2.2	3.72	1.18	-1.44	2.7	1.84	1.34	2.52	1.53	4.27	0.91	1.87	3.06	3.42
OPM %	2.96	2.29	-1.57	3.14	1.67	-3.89	1.64	3.54	0.93	-0.68	3.53	3.18	2.63	1.55	2.45	5.6	0.77	1.56	2.18	2.54
Other Income	1.72	-0.43	4.18	0.79	1.55	7.54	0.68	0.02	1.58	5.14	0.29	0.84	0.7	0.84	0.48	-0.94	0.85	1.13	0.13	0.81
Interest	1.67	1.78	0.92	1.26	1.04	1.3	0.58	0.49	0.96	0.4	0.47	0.41	0.42	0.2	0.71	0.59	0.55	0.43	0.49	0.61
Depreciation	0.85	0.85	0.83	0.69	0.49	0.41	0.9	1.51	0.47	1.15	1.06	1.27	0.89	1.02	0.55	0.42	0.41	0.59	0.5	0.5
Profit before tax	0.52	1.28	0.92	1.48	1.73	1.62	1.4	1.74	1.33	2.15	1.46	1	0.73	2.14	0.75	2.32	0.8	1.98	2.2	3.12
Tax %	-98.08	-21.88	38.04	31.08	20.81	71.6	48.57	8.62	6.77	-0.47	30.14	-22	0	83.18	-33.33	9.05	0	137.88	11.36	8.97
Net Profit	1.02	1.56	0.57	1.02	1.37	0.47	0.72	1.6	1.24	2.15	1.02	1.23	0.72	0.36	1	2.12	0.8	-0.76	1.95	2.84
Net Profit Growth % (QoQ)	-34.6%	173.7%	-44.1%	-25.5%	191.5%	-34.7%	-55%	29%	-42.3%	110.8%	-17.1%	70.8%	100%	-64%	-52.8%	165%	205.3%	-139%	-31.3%	-
Net Profit Growth % (YoY)	-25.5%	231.9%	-20.8%	-36.3%	10.5%	-78.1%	-29.4%	30.1%	72.2%	497.2%	2%	-42%	-10%	147.4%	-48.7%	-25.4%	-	-	-	-
TTM Net Profit	4.17	4.52	3.43	3.58	4.16	4.03	5.71	6.01	5.64	5.12	3.33	3.31	4.2	4.28	3.16	4.11	4.83	4.03	4.79	0
EPS in Rs	0.36	0.55	0.2	0.36	0.48	0.17	0.25	0.57	0.44	0.77	0.4	0.48	0.28	0.14	0.39	0.84	0.32	-0.3	0.77	1.21

Profit and Loss

	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	Mar 2013
Sales	472	474	396	419	493	348	298	354	349	396	246	213	200	172
Sales Growth %	-0.4%	19.8%	-5.6%	-15%	41.4%	17.1%	-16%	1.5%	-11.8%	61%	15.3%	6.9%	15.9%	32.1%
Expenses	465	471	391	411	481	344	294	347	342	386	245	212	198	170
Operating Profit	7	3	4	8	11	5	3	8	8	10	1	1	1	2
OPM %	1.5	0.6	1.1	1.8	2.3	1.3	1.1	2.2	2.2	2.4	0.4	0.6	1	1
Other Income	6	10	7	3	3	7	7	4	3	3	3	3	2	0
Interest	5	5	4	3	2	2	2	2	2	4	2	1	1	1
Depreciation	3	2	2	2	2	1	1	1	1	1	1	1	1	1
Profit before tax	5	6	5	6	10	8	7	9	8	8	2	1	1	1
Tax %	27	34	12	37	35	21	20	27	25	31	29	23	22	27
Net Profit	4	4	5	4	7	7	6	7	6	5	1	1	1	1
Net Profit Growth %	-	-20%	25%	-42.9%	-	16.7%	-14.3%	16.7%	20%	400%	-	-	-	-
EPS in Rs	1.4	1.42	1.67	1.49	2.58	2.78	2.48	2.8	2.64	3.02	0.77	0.65	0.62	0.39
Dividend Payout %	0	0	0	0	0	0	0	4	0	0	0	0	0	0

Cash Flows

	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	Mar 2013
Cash from Operating Activity	10	10	-3	-1	0	5	3	1	-20	1	6	3	0	3
Cash from Investing Activity	-12	-6	-2	0	-3	-3	-1	-1	-1	-5	-3	-2	2	-3
Cash from Financing Activity	2	-4	6	1	2	-2	-2	-2	23	4	-2	-2	-1	-1
Net Cash Flow	0	0	1	1	0	0	0	-3	2	-1	1	-1	0	-1

Balance Sheet

	Mar 2026	Sep 2025	Mar 2025	Sep 2024	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	Mar 2013
Equity Capital	28	28	28	28	28	25	25	23	23	23	23	18	17	17	17	17
Reserves	122	120	110	108	105	92	88	75	69	63	57	31	20	19	18	17
Borrowings	50	51	35	39	31	38	14	18	18	16	3	10	15	11	6	5
Other Liabilities	97	94	117	100	139	136	117	116	84	43	86	83	74	69	67	69
Total Liabilities	297	294	291	275	303	291	245	233	194	146	170	142	125	115	107	107
Fixed Assets	26	25	16	13	13	14	14	14	12	12	12	12	8	6	4	4
CWIP	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Investments	2	2	2	1	1	0	0	0	0	0	0	0	0	0	0	3
Other Assets	269	267	272	260	289	277	230	218	181	133	157	130	117	109	102	99
Total Assets	297	294	291	275	303	291	245	233	194	146	170	142	125	115	107	107

Delivery

Delivery Data: AAREYDRUGS

#	Date	75 30% 97	Value (Cr)	Q/T 762	Del 56	Del 1
1	4-Sep	96	1	132	76	1
2	3-Sep	94	1	164	69	1
3	2-Sep	92	1	83	53	1
4	1-Sep	92	6	406	22	1
5	31-Aug	88	1	92	66	1
6	28-Aug	89	3	416	80	3
7	27-Aug	85	2	338	80	1
8	26-Aug	81	2	261	82	1
9	25-Aug	77	1	164	69	1
10	24-Aug	78	0	76	69	0
11	21-Aug	81	6	509	21	1
12	20-Aug	81	0	73	75	0
13	19-Aug	83	0	69	69	0
14	18-Aug	82	6	1456	22	1
15	17-Aug	86	1	564	92	1

Daily Market Cap

Date	Total Market Cap	Change	Chg %
04-Sep	272c	3c	1.06
03-Sep	269c	37c	15.79
14-Aug	233c	6c	2.38
13-Aug	238c	3c	1.20
12-Aug	235c	3c	1.37
11-Aug	239c	0	0
10-Aug	239c	28L	0.12
06-Aug	239c	6c	2.73
05-Aug	233c	6c	2.37
04-Aug	238c	17c	7.89
31-Jul	221c	11c	5.07
30-Jul	210c	9c	3.95
28-Jul	219c	3c	1.58
27-Jul	215c	0	0

Stock Checklist

Price is above from 52 week high low average: 92%

Stock is trading above all short term SMAs: YES

Stock is trading above all long term SMAs: YES

Stock is Consistently Improving Long Term: NO

FII purchased in last quarter: YES

Promoters are buying the stock: NO

Mutual Fund Holdings

No mutual fund holding data available.

Strategy Builder

Bulk Deals

Events

News

Exchange Filings

Annual Reports

Ratings & Research Reports

Concalls

Announcements

Corporate Announcements

NseIndia | Trendlyne | Screener | TradingView